A Multicenter, Randomized, Double-blind, Vehicle Controlled Phase II Clinical Study to Evaluate t… (NCT07598383) | Clinical Trial Compass
Not Yet RecruitingPhase 2
A Multicenter, Randomized, Double-blind, Vehicle Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 Gel in Adult Subjects With Mild to Moderate Atopic Dermatitis
China120 participantsStarted 2026-05-30
Plain-language summary
This is a multicenter, randomized, double-blind, vehicle controlled phase II clinical study to evaluate the efficacy and safety of VC005 gel in adult subjects with mild to moderate atopic dermatitis
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Subjects fully understand this study, are able to follow the relevant procedures of the trial, voluntarily participate in the clinical trial, and sign the informed consent form (ICF);
. The age requirement for signing the ICF is 18 years old or above, with no gender restrictions;
. During screening, the diagnosis of atopic dermatitis should be met according to the Hanifin-Rajka criteria.
Exclusion criteria
. Patients judged by the investigator to have an unstable course of Atopic Dermatitis (AD) (spontaneous improvement or rapid deterioration) within 2 weeks before baseline;
. Patients with skin lesions limited to the hands or feet at screening and baseline, with no prior history of involvement in other typical areas (such as the face or flexural folds);
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Changes in EASI（Eczema area and severity index） from baseline
. Skin damage or abnormalities that may affect the evaluation of the investigational drug administration site (e.g., hyperpigmentation, large-area scars, tattoos, etc. at the affected site);
. Presence of skin diseases at screening and baseline that may affect the evaluation of the administration site, including but not limited to: psoriasis, acne, skin cancer, generalized erythroderma, Netherton's syndrome, etc.;
. Patients with a history of malignant tumors, with the exception of: cervical carcinoma in situ, non-metastatic cutaneous squamous cell carcinoma or basal cell carcinoma, or non-metastatic papillary thyroid carcinoma that have been completely resected with no evidence of recurrence for more than 5 years of survival.